12 hours ago
1
Hailshadow/iStock via Getty Images
- New data from an open-label study of BridgeBio Pharma's (NASDAQ:BBIO) Attruby (acoramidis) showed that the drug led to a significant reduction in cardiovascular mortality in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM).
- At 42 months post-randomization, Attruby led to a 44% reduction
English (US) ·